SOPHiA GENETICS SA (SOPH)
Market Cap | 218.58M |
Revenue (ttm) | 64.49M |
Net Income (ttm) | -71.40M |
Shares Out | 66.44M |
EPS (ttm) | -1.09 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 5,076 |
Open | 3.260 |
Previous Close | 3.260 |
Day's Range | 3.250 - 3.300 |
52-Week Range | 2.700 - 7.370 |
Beta | 0.99 |
Analysts | Strong Buy |
Price Target | 7.00 (+112.77%) |
Earnings Date | Nov 5, 2024 |
About SOPH
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, Nor... [Read more]
Financial Performance
In 2023, SOPHiA GENETICS's revenue was $62.37 million, an increase of 31.14% compared to the previous year's $47.56 million. Losses were -$78.98 million, -9.68% less than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for SOPH stock is "Strong Buy." The 12-month stock price forecast is $7.0, which is an increase of 112.77% from the latest price.
News
SOPHiA GENETICS Launches MSK-IMPACT® powered with SOPHiA DDM™ at AMP 2024
Launch of new application enables global access to highly recognized solid tumor profiling assay BOSTON and ROLLE, Switzerland , Nov. 21, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-n...
SOPHiA GENETICS SA (SOPH) Q3 2024 Earnings Call Transcript
SOPHiA GENETICS SA (NASDAQ:SOPH) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Kellen Sanger - Head of Strategy and Investor Relations Jurgi Camblong - Co-Founder ...
SOPHiA GENETICS Promotes Ross Muken to President and Appoints George Cardoza as Chief Financial Officer
BOSTON and ROLLE, Switzerland , Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previo...
SOPHiA GENETICS Reports Third Quarter 2024 Results
Clinical growth reaccelerates with record analysis volume; Cash burn improves 39% BOSTON and ROLLE, Switzerland , Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software c...
SOPHiA GENETICS to Announce Financial Results for Third Quarter 2024 on November 5, 2024
BOSTON and ROLLE, Switzerland , Oct. 22, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its ...
SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024
Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to derive the most benefit from combination immunotherapy BOSTON and ROLLE, Switzer...
SOPHiA GENETICS Announces Poster Presentations at ESMO 2024
Research presented will include the applications of new diagnostic tools and machine learning multimodal signatures in clinical trials BOSTON and ROLLE, Switzerland , Sept. 12, 2024 /PRNewswire/ -- SO...
SOPHiA GENETICS Announces Updates on SOPHiA UNITY at ESMO 2024
The global collective intelligence network aims to accelerate precision oncology research and care BOSTON and ROLLE, Switzerland , Sept. 12, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a clou...
SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing
The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 months BOSTON and ROLLE, Switzerland , Sept. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nas...
SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024
The companies share how their collaboration enables clinical trial enrollment for a novel cancer therapy for oncogene amplified cancers in development by Boundless Bio BOSTON and ROLLE, Switzerland , ...
SOPHiA GENETICS Unveils New Generation of the SOPHiA DDMTM Platform at Morgan Stanley Healthcare Conference 2024
New generation of SOPHiA DDM TM integrates latest advancements in data processing and technology to deliver elevated experience and capabilities to customers BOSTON and ROLLE, Switzerland , Sept. 4,...
SOPHiA GENETICS to Present at the 22nd Annual Morgan Stanley Healthcare Conference and 9th Annual TD Cowen FutureHealth Conference
BOSTON and ROLLE, Switzerland , Aug. 28, 2024 /PRNewswire/ -- SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced presentations at the 22nd Annual Mo...
SOPHiA DDM™ Platform Certified Under IVDR
Regulatory milestone validates the SOPHiA DDM™ Platform as diagnostic tool in select markets BOSTON and ROLLE, Switzerland , Aug. 14, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-nativ...
SOPHiA GENETICS Reports Second Quarter 2024 Results
Strength in U.S. Growth Offset by Challenges in BioPharma and EMEA; Strong Cost Management B uffers Loss BOSTON and ROLLE, Switzerland , Aug. 6, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a ...
SOPHiA GENETICS Announces L'hôpital Universitaire Avicenne is Live on SOPHiA DDM™
The hospital will use the SOPHiA DDM™ Platform to enhance its testing and research of blood cancers BOSTON and ROLLE, Switzerland , July 29, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a clou...
SOPHIA GENETICS Announces Expanded Relationship with Canada-Based OncoHelix
OncoHelix is the first laboratory in Canada to adopt MSK-ACCESS® powered with SOPHiA DDM™ BOSTON and ROLLE, Switzerland , July 24, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native ...
SOPHiA GENETICS Announces Expanded Relationship with Canada-Based OncoHelix
OncoHelix is the first laboratory in Canada to adopt MSK-ACCESS® powered with SOPHiA DDM™ BOSTON and ROLLE, Switzerland , July 24, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native h...
SOPHiA GENETICS to Announce Financial Results for Second Quarter 2024 on August 6, 2024
BOSTON and ROLLE, Switzerland , July 23, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its ...
India-Based Dhiti Omics is Now Live on SOPHiA DDM™
The diagnostics company has implemented the SOPHiA DDM™ Platform to enhance its solid tumor testing BOSTON and ROLLE, Switzerland , July 4, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud...
SOPHiA GENETICS Publishes Results of 2024 Annual General Meeting
BOSTON and ROLLE, Switzerland, June 24, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a healthcare technology company and a leader in data-driven medicine, is pleased to announce that it...
SOPHiA GENETICS Launches New Residual Acute Myeloid (RAM) Application
Novel application supports measurable residual disease (MRD) testing to help monitor cancer and stay ahead of relapse BOSTON and ROLLE, Switzerland , June 24, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nas...
SOPHiA GENETICS Announces Kepler Uniklinikum is Live on SOPHiA DDM™ Platform
The Hospital will use SOPHiA DDM™ to enhance its testing and research of blood cancers BOSTON and ROLLE, Switzerland , June 13, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native heal...
SOPHiA GENETICS Launches Global Consortium, SOPHiA UNITY, to Accelerate Cancer Research, Drug Development, and Data-Driven Patient Care
New collective intelligence network to enable the most advanced research in oncology in support of precision medicine BOSTON and ROLLE, Switzerland , May 30, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasd...
SOPHiA GENETICS to Launch New Whole Genome Sequencing Capabilities
In collaboration with Microsoft and NVIDIA, SOPHiA GENETICS is developing a comprehensive whole genome analytical solution BOSTON and ROLLE, Switzerland , May 29, 2024 /PRNewswire/ -- SOPHiA GENETICS ...
SOPHiA GENETICS Announces Instituto Mário Penna as New Customer
The hospital will enhance its testing and research of blood cancers with the SOPHiA DDM™ Platform BOSTON and ROLLE, Switzerland , May 20, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-n...